TLR2 and cancer: Three agents with TLR agonist activity have been approved by the FDA for cancer treatments including bacillus Calmette-Guerin (TLR2&4 agonists mixture), monophosphoryl lipid A (TLR2/4 agonists mixture), and imiquimod (TLR7 agonist) [2].